- Home
- ATLC vs CRMD Comparison
ATLC vs CRMD Comparison
Compare ATLC & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATLC | CRMD |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 863.2M | 958.1M |
| IPO Year | 1999 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ATLC | CRMD |
|---|---|---|
| Price | $54.25 | $7.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $87.50 | $15.29 |
| AVG Volume (30 Days) | 71.6K | ★ 4.2M |
| Earning Date | 03-12-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.57 | N/A |
| EPS | ★ 5.63 | 2.25 |
| Revenue | ★ $498,496,000.00 | $214,303,672.00 |
| Revenue This Year | $404.07 | $629.55 |
| Revenue Next Year | $60.81 | $8.34 |
| P/E Ratio | $9.34 | ★ $3.61 |
| Revenue Growth | 33.26 | ★ 1647.67 |
| 52 Week Low | $41.37 | $5.60 |
| 52 Week High | $78.91 | $17.43 |
Technical Indicators
Market Signals| Indicator | ATLC | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.34 | 40.84 |
| Support Level | $50.90 | $7.66 |
| Resistance Level | $61.54 | $8.53 |
| Average True Range (ATR) | 2.62 | 0.39 |
| MACD | -0.51 | 0.18 |
| Stochastic Oscillator | 36.04 | 65.40 |
Price Performance
Historical ComparisonAbout ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.